ASBP

Aspire Biopharma Holdings, Inc. (ASBP) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Growth

Revenue per share remains extremely low at 0.094 and asset turnover is just 0.007, indicating minimal top-line productivity.

No recent news or fresh metrics indicate an improving growth trajectory.

Profitability

TTM margins remain deeply negative, with EBIT margin at -64.7% and net profit margin at -113.1%.

Return on invested capital is still negative at -0.60, showing the business is not generating economic returns on capital.

Financial Health

Liquidity is strong, with a current ratio of 8.0 and cash ratio of 7.2.

The balance sheet shows no debt (debt-to-equity 0) and net current asset value of 11.7M, supporting near-term solvency.

Shareholder Returns

There is no dividend yield and no evidence of sustained shareholder return policy in the fresh data.

Free cash flow remains negative on a per-share basis, limiting capital return capacity.

Valuation

Valuation screens as optically cheap on book value, with price-to-book at 0.79 and price-to-sales at 10.63.

However, negative earnings and cash flow metrics make the valuation difficult to anchor on durable fundamentals.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →